Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins
Improvement in disease activity across four classes of biologics is associated with enhanced PON1 activity, which has significant implications for cardiovascular safety.
Authors
- Jeffrey R. Curtis (ORCID: https://orcid.org/0000-0002-8907-8976)
- Ellen O’Connor
- Joel M. Kremer (ORCID: https://orcid.org/0000-0001-6674-9901)
- David Meriwether (ORCID: https://orcid.org/0000-0001-6270-5645)
- Christina Charles‐Schoeman (ORCID: https://orcid.org/0000-0002-1768-7019)
- Dawoud Sulaiman
- Amir A. Razmjou (ORCID: https://orcid.org/0000-0002-5245-3998)
- Ani Shahbazian (ORCID: https://orcid.org/0009-0000-9808-4406)
- Dimitrios A. Pappas (ORCID: https://orcid.org/0000-0001-8338-027X)
- Srinivasa T. Reddy (ORCID: https://orcid.org/0000-0003-2959-9531)
- David A. Elashoff (ORCID: https://orcid.org/0000-0002-5865-8580)
- Jennifer Wang (ORCID: https://orcid.org/0000-0002-2556-9100)
- Rong Guo (ORCID: https://orcid.org/0000-0003-0000-2543)
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
- UCLA Medical Center (US)
- University of Alabama at Birmingham (US)
- Research Foundation for the State University of New York (US)
- Navitas Systems (United States) (US)
Publication Details
- Journal
- RMD Open
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004829
- Citations
- 2
- Primary Topic
- Paraoxonase enzyme and polymorphisms
- Type
- article
- Field-Weighted Citation Impact
- 0.76
Funders
- Bristol-Myers Squibb Foundation
- Bristol-Myers Squibb